Sign In
Buy IMRX
$4.44
+0.0300 (+0.680%)
At Close: Jun 22, 2026
Immuneering Appoints Andrew Gengos as Chief Financial Officer
07:30am, Monday, 15'th Jun 2026
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- I
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
10:51am, Friday, 12'th Jun 2026
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
07:30am, Thursday, 11'th Jun 2026
Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary end
Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript
02:14pm, Monday, 01'st Jun 2026
Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Can
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
07:35am, Friday, 15'th May 2026
- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting - - Pivotal
Immuneering Corporation: Updates Inbound At The End Of The Month
07:59am, Tuesday, 12'th May 2026
Immuneering Corporation (IMRX) presents promising early data in frontline metastatic pancreatic cancer with its MEK inhibitor atebimetinib, benchmarking favorably against Revolution Medicines. IMRX's
- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health -
Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors rarel
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears
03:02am, Tuesday, 14'th Apr 2026
Immuneering (NASDAQ: IMRX) CEO Benjamin J. Zeskind told investors at a Needham conference session that 2026 has started with what he described as "extraordinary" early survival results for the company
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
04:05pm, Monday, 06'th Apr 2026
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today anno
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Analysts
02:22am, Monday, 23'rd Mar 2026
Shares of Immuneering Corporation (NASDAQ: IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat rep
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability
Oxford BioMedica (OTCMKTS:OXBDF) and Immuneering (NASDAQ:IMRX) Financial Contrast
02:24am, Thursday, 12'th Mar 2026
Oxford BioMedica (OTCMKTS:OXBDF - Get Free Report) and Immuneering (NASDAQ: IMRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two co
